Inclusion Criteria:

- Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's
lymphoma (NHL) of any histologic subtype

- Indolent

- Follicular small cleaved cell

- Follicular mixed cell

- Small lymphocytic

- Mucosa-associated lymphoid tissue (MALT)

- Monocytoid B-cell

- Waldenstrom's macroglobulinemia

- Aggressive

- Follicular large cell

- Diffuse large cell

- Immunoblastic

- Mantle cell

- Ki-1+ NHL

- Peripheral T-cell

- Angiocentric and angioimmunoblastic

- Transformed lymphoma

- Bidimensionally measurable disease

- No more than 3 prior treatment regimens as follows:

- Primary radiotherapy is 1 regimen

- Combined therapy with radiotherapy and chemotherapy is 1 regimen

- Alternating therapy is 1 regimen

- No known brain metastases

- Performance status - ECOG 0-2

- Performance status - Karnofsky 50-100%

- WBC count at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin normal

- SGOT/SGPT no greater than 2.5 times upper limit of normal

- Creatinine normal

- Creatinine clearance at least 60 mL/min

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- No neuropathy greater than grade 1

- No history of allergy to platinum compounds or antiemetics

- No uncontrolled illness

- No active infection

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No concurrent colony-stimulating factors during first course of therapy

- At least 4 weeks since prior chemotherapy

- At least 4 weeks since prior radiotherapy

- No other concurrent investigational drugs

- No concurrent antiretroviral therapy for HIV-positive patients